118 related articles for article (PubMed ID: 29444555)
1. WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes.
Arif SH; Pandith AA; Tabasum R; Ramzan AU; Singh S; Siddiqi MA; Bhat AR
J Neurosurg Sci; 2018 Feb; ():. PubMed ID: 29444555
[TBL] [Abstract][Full Text] [Related]
2. Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and
Arif SH; Pandith AA; Tabasum R; Ramzan AU; Singh S; Siddiqi MA; Bhat AR
Asian J Neurosurg; 2018; 13(1):46-52. PubMed ID: 29492119
[TBL] [Abstract][Full Text] [Related]
3. WHITDRAWAL: Comparative efficacy of sirolimus-eluting stents and paclitaxel-eluting stents in East Asian versus non-East Asian patients: a systematic review and meta-analysis.
Zhao R; Lu Q; Yang R; DU J; Deng S; She Q
Minerva Cardioangiol; 2017 Jan; ():. PubMed ID: 28146142
[TBL] [Abstract][Full Text] [Related]
4. Statement of Retraction: "Mohamad Goldust, Mahnaz Talebi, Jafar Majidi, Mohammad Amin Rezazadeh Saatlou, and Elham Rezaee. Evaluation of antiphospholipid antibodies in youths suffering from cerebral ischemia.".
Lyons K; Pahwa R
Int J Neurosci; 2013 Aug; 123(8):597. PubMed ID: 23611513
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
6. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
8. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
[TBL] [Abstract][Full Text] [Related]
10. Retracted: Reversal of Spinal Cord Ischemia Following Endovascular Thoracic Aortic Aneurysm Repair with Hyperbaric Oxygen and Therapeutic Hypothermia.
Urquieta E; Jye Poi M; Varon J; Lin PH
Ther Hypothermia Temp Manag; 2015 Dec; ():. PubMed ID: 26654155
[TBL] [Abstract][Full Text] [Related]
11. Retraction notice.
J Int Med Res; 2018 Apr; 46(4):NP1. PubMed ID: 29540088
[TBL] [Abstract][Full Text] [Related]
12. Retraction: Nucleophagy in Human Disease: Beyond the Physiological Role. [Tohoku J. Exp. Med., 2018, 244 (1), 75-81. doi: 10.1620/tjem.244.75. Review.].
Tohoku J Exp Med; 2018 Feb; 244(2):175. PubMed ID: 29467341
[TBL] [Abstract][Full Text] [Related]
13. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal Notice: Applying Peer Mentoring to Improve Learning Human Anatomy.
Nikolenko VN; Rizaeva NA; Oganesyan MV; Kudryashova VA; Dubrovina PI; Dubovets AA; Bolotskaya AA; Bulygin KV; Muresanu C; Somasundaram SG; Kirkland CE; Aliev G
Cent Nerv Syst Agents Med Chem; 2021 Feb; ():. PubMed ID: 33583385
[TBL] [Abstract][Full Text] [Related]
16. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
17. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
18. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
[TBL] [Abstract][Full Text] [Related]
19. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
[TBL] [Abstract][Full Text] [Related]
20. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
